HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK)

HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (5)

  • Species

    Human (5)

  • Tag

    His Tag & Avi Tag (2)His Tag (3)

  • Conjugate

    Biotin-labeled (1)Unconjugated (2)AF488 Labeled (1)PE Labeled (1)

HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) Background

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*1101 KRASG12D (VVVGADGVGK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M, and VVVGADGVGK peptide of the KRASG12D.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
VVN-001VVN001; VVN-001Phase 3 ClinicalVivaVision Biotech IncDry Eye Syndromes; Xerophthalmia
Details
P-28-RP-28- RPhase 1 ClinicalCanimguide TherapeuticsHead and Neck Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
OdulimomabApprovedImmunotech SASAntilfaFranceGraft vs Host Disease; Rejection of renal transplantationnull1997-01-01Rejection of renal transplantation; Graft vs Host Disease
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information